IRIS
RUZZO, ANNAMARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.860
EU - Europa 7.887
AS - Asia 5.596
SA - Sud America 486
Continente sconosciuto - Info sul continente non disponibili 342
AF - Africa 87
OC - Oceania 52
AN - Antartide 2
Totale 28.312
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.692
CN - Cina 2.712
GB - Regno Unito 2.532
SG - Singapore 1.533
UA - Ucraina 1.208
IT - Italia 949
FR - Francia 682
TR - Turchia 520
SE - Svezia 513
RU - Federazione Russa 494
DE - Germania 488
FI - Finlandia 408
BR - Brasile 385
VN - Vietnam 248
IE - Irlanda 239
PL - Polonia 121
HK - Hong Kong 113
IN - India 109
CA - Canada 98
AT - Austria 79
KR - Corea 58
AU - Australia 46
BD - Bangladesh 44
NL - Olanda 43
JP - Giappone 41
MX - Messico 40
AR - Argentina 32
BE - Belgio 29
PK - Pakistan 29
ES - Italia 28
ZA - Sudafrica 28
ID - Indonesia 24
EC - Ecuador 23
IQ - Iraq 23
SA - Arabia Saudita 20
IR - Iran 17
EU - Europa 15
VE - Venezuela 13
JO - Giordania 11
PH - Filippine 11
TN - Tunisia 11
UZ - Uzbekistan 11
EG - Egitto 10
RO - Romania 9
AE - Emirati Arabi Uniti 8
BG - Bulgaria 8
MA - Marocco 8
CL - Cile 7
CO - Colombia 7
LT - Lituania 7
TG - Togo 7
AL - Albania 6
NZ - Nuova Zelanda 6
PE - Perù 6
UY - Uruguay 6
DZ - Algeria 5
KE - Kenya 5
KG - Kirghizistan 5
MD - Moldavia 5
MY - Malesia 5
PA - Panama 5
TW - Taiwan 5
AM - Armenia 4
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
DO - Repubblica Dominicana 4
GR - Grecia 4
IL - Israele 4
JM - Giamaica 4
LK - Sri Lanka 4
LV - Lettonia 4
NG - Nigeria 4
OM - Oman 4
PY - Paraguay 4
TH - Thailandia 4
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
BO - Bolivia 3
CH - Svizzera 3
DK - Danimarca 3
GD - Grenada 3
HN - Honduras 3
HR - Croazia 3
LU - Lussemburgo 3
MM - Myanmar 3
NP - Nepal 3
SK - Slovacchia (Repubblica Slovacca) 3
CI - Costa d'Avorio 2
CR - Costa Rica 2
ET - Etiopia 2
GE - Georgia 2
GT - Guatemala 2
HU - Ungheria 2
KZ - Kazakistan 2
LB - Libano 2
MO - Macao, regione amministrativa speciale della Cina 2
PT - Portogallo 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
Totale 27.962
Salva come PNG Salva come JPEG
Città #
Southend 2.274
Fairfield 1.665
Ashburn 1.312
Woodbridge 1.291
Houston 1.168
Jacksonville 963
Singapore 768
Seattle 719
Ann Arbor 679
Cambridge 670
Wilmington 647
Nanjing 607
San Jose 566
Chandler 515
Izmir 400
Beijing 366
Dallas 361
Boardman 269
Dublin 240
Nanchang 215
New York 172
Helsinki 169
Lauterbourg 151
Los Angeles 151
Princeton 144
Bremen 135
Urbino 118
Council Bluffs 111
Shenyang 108
Hong Kong 106
Tianjin 102
San Mateo 101
Kunming 98
Düsseldorf 91
Hebei 90
Kraków 90
Ho Chi Minh City 88
Moscow 84
Jiaxing 73
Istanbul 70
Changsha 67
San Diego 67
Vienna 65
Santa Clara 64
Buffalo 59
Munich 59
San Francisco 58
Shanghai 58
Hangzhou 56
London 52
Chicago 47
Guangzhou 45
Hanoi 44
Seongnam 44
The Dalles 43
São Paulo 42
Velikiy Novgorod 42
Toronto 39
Rome 36
Milan 35
Jinan 34
Brooklyn 32
Ancona 30
Denver 29
Falls Church 29
Tokyo 29
Lanzhou 28
Orem 28
Ningbo 27
Atlanta 26
Frankfurt am Main 26
Nuremberg 25
Changchun 24
Warsaw 24
Strasbourg 23
Zhengzhou 23
Brussels 22
Stockholm 22
Phoenix 21
Boston 19
Dearborn 19
Montreal 19
Rimini 19
Poplar 18
Sydney 18
Rio de Janeiro 17
Johannesburg 16
Pesaro 16
Riyadh 16
Mülheim 15
Redwood City 15
Taizhou 15
Augusta 14
Chennai 14
Manchester 14
Mexico City 14
Acton 13
Amsterdam 13
Cesena 13
Melbourne 13
Totale 19.801
Salva come PNG Salva come JPEG
Nome #
2196 Polymorphisms and miRNAs targeting CLOCK gene affect gender-related survival in metastatic colorectal cancer (mCRC) patients (pts) 348
XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT 315
C-MET gene copy number variation (CNV) analysis by quantitative PCR (qPCR) assay in Caucasian patients with gastric cancer (GC). 314
TS, MTHFR AND XRCC1 GENETIC VARIANTS INFLUENCE THE OUTCOME OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK 312
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients 298
The Mutational Status Of Genes Involved In DNA Repair and Folate Pathway Predicts Overall Survival Of Patients With Low-Risk, Untreated Myelodysplastic Syndrome 286
Endogastric capsule for E-cadherin gene (CDH1) promoter hypermethylation assessment in DNA from gastric juice of diffuse gastric cancer patients. 269
Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial 266
VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 262
Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the progression of colorectal cancer (CRC) 262
Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy 260
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. 257
Effect of polymorphisms and miRNAs targeting CLOCK gene on gender-related survival in metastatic colorectal cancer (mCRC) patients (pts). 250
BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 248
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan 244
VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 243
KRAS-mutated patients with liver-only metastatic colorectal cancer treated with Bevacizumab and chemotherapy. Functional analysis of TP53 mutations and outcomes 242
Genetic modulation of the Interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy 242
Evaluation of MET using FISH, IHC, or mass spectrometry as a prognostic biomarker in patients with gastroesophageal cancer 241
THE EXPRESSION OF THE KRAS mRNA ISOFORMS 4A AND 4B IN PLASMA: A COMPARISON BETWEEN LUNG ADENOCARCINOMA PATIENTS AND HEALTHY DONORS THROUGH LIQUID BIOPSY 230
A Novel Homozygous Variant in the Fork-Head-Associated Domain of Polynucleotide Kinase Phosphatase in a Patient Affected by Late-Onset Ataxia With Oculomotor Apraxia Type 4 228
Assignment of the hexokinase type 3 gene (HK3) to human chromosome band 5q35.3 by somatic cell hybrids and in situ hybridization 227
MET as a prognostic biomarker of survival in a large cohort of patients with gastroesophageal cancer (GEC) 227
Association of Thymidylate Synthase Polymorphisms with Gastric Cancer Susceptibility 226
An erythroid-specific exon is present in the human hexokinase gene 224
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition 224
Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC) 223
Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes 220
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. 219
Glucose metabolism enzymes gene expression analysis and selective metabolism advantage in the clinical progression of colorectal cancer (CRC) 219
BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (mCRC) PATIENTS 219
Hexokinase 218
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer 217
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer 217
TP53 mutation analysis in gastric cancer and clinical outcomes of patients with metastatic disease treated with Ramucirumab-Paclitaxel or standard chemotherapy 217
Sex-Related Differences in Impact On Safety Of Pharmacogenetic Profile For Colon Cancer Patients Treated With FOLFOX-4 or XELOX Adjuvant Chemotherapy 216
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. 215
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients 215
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma 215
Structure of the human hexokinase type I gene and nucleotide sequence of the 5' flanking region 213
High resolution melting (HRM) analysis for the detection of ER22/23EK, BclI, and N363S polymorphisms of the glucocorticoid receptor gene. 213
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 212
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. 211
Amplificazione enzimatica specifica di una regione di DNA strettamente associata alla Corea di Huntington 210
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 210
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients 209
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. 209
VEGF gene polymorphisms and susceptibility to colorectal cancer disease in italian population 208
Evaluation of Period 2 gene (PER-2) biologic profile in advanced colorectal cancer (ACC) patients treated with chronomodulated chemotherapy 208
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes 207
The G/A Nucleotide Change at cDNA Position 2494 in the E-Cadherin Gene (CDH1): Analysis in Italian Patients 206
Molecular analysis of G6PD variants in northern Italy: a study on the population from the Ferrara district. 206
Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR 205
NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population 204
Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy 203
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer 203
High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease 202
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. 199
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy 197
The genotype of a new linked DNA marker, MP6d-9, is related to the clinicalcourse of cystic fibrosis. 197
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer 197
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. 197
Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients 195
Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients 195
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. 194
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomized, phase III adjuvant TOSCA trial in high-risk colon cancer patients. 194
Emerging biomarkers in bladder cancer identified by network analysis of transcriptomic data 193
PHARMACOGENETIC PROFILING FOR TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINES. FINAL REPORT FROM AN ANCILLARY PROTOCOL TO THE TOSCA TRIAL 192
Structure of the 5' region of the human hexokinase type I (HKI) gene and identification of an additional testis-specific HKI mRNA 192
Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer 192
PTEN EXPRESSION AND KRAS MUTATIONS AS PREDICTORS OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN (CETIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 191
Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"? 191
K-RAS STATUS IN PRIMARY COLORECTAL TUMOURS CORRELATE WITH K-RAS STATUS IN RELATED METASTATIC SITES: IMPLICATIONS FOR TREATMENT WITH ANTI-EGFR ANTIBODIES IN CLINICAL SETTING 191
BRAF mutations and EGFR Intron-1 L/L genotype are associated with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients 190
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy 189
XRCC1 399GG GENOTYPE PREDICTS SIGNIFICANTLY LONGER OVERALL SURVIVAL AND LONG LASTING CR IN RESISTANT LYMPHOMA TREATED WITH BENDA-BEAM AND ASCT 188
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice 187
Molecular analysis of G6PD variants in northern Italy: a study on the population from the Ferrara district 187
Gender related differences in polymorphism and miRNA targeting CLOCK genes in metastatic colorectal cancer patients 187
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs 184
Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy 180
Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients 179
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patientstreated with surgery and adjuvant chemotherapy. 179
[Construction of an apparatus for pulsed field electrophoresis for the analysisof high molecular weight DNA] 178
Pharmacogenetic profiling for toxicity of oxaliplatin and fluoripyrimidines. An Ancillary protocol to the TOSCA trial 178
Glucose-6-phosphate dehydrogenase nucleotide 1311 polymorphism in central Italy(Marche Region). 178
ANALYSIS OF PTEN EXPRESSION AND KRAS MUTATIONS ON PRIMARIES (PRIM) AND METASTASES (METS) TO PREDICT BENEFIT FROM CETUXIMAB PLUS IRINOTECAN (CETIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 177
Predictive and prognostic role of E-cadherin expression in patients with advanced gastric cancer treated with palliative chemotherapy. 175
Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer 174
TS, MTHFR AND XRCC1 GENETIC VARIANTS AFFECT THE CLINICAL COURSE OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK 174
Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk italian population 173
Patients treated with FOLFOX-4 or XELOX chemotherapy with high-risk stage II and III colon cancer (TOSCA trial): a different impact of pharmacogenetic profile on toxicity in women and men 172
Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib 170
Structure of the human hexokinase type I gene. 169
Period 2 (PER-2) biologic profile in advanced colorectal cancer (ACC) patients (pts) 168
HOST GENETIC VARIANTS IN THE INSULIN GROWTH FACTOR BINDING PROTEIN-3 IMPACT ON SURVIVAL OF PATIENTS WITH ADVANCED GASTRIC CANCER TREATED WITH PALLIATIVE CHEMOTHERAPY 166
Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial 166
Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity? 166
Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer 166
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice 165
Totale 21.186
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.737
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.737
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.637 0 188 210 223 82 69 76 95 107 84 81 422
2022/20231.954 286 78 22 201 252 413 7 103 360 70 96 66
2023/2024656 68 52 33 46 82 166 27 45 8 56 7 66
2024/20252.292 116 87 479 147 76 234 282 115 249 216 167 124
2025/20265.451 449 527 637 908 469 366 710 183 405 411 272 114
2026/2027319 189 130 0 0 0 0 0 0 0 0 0 0
Totale 28.312